sepsis AKI
Conditions
Interventions
Nafamostat group:Anticoagulation with Nafamostat during CRRT
Citric acid group:Anticoagulation with Citric acid during CRRT
Sponsors
Zhongnan Hospital of Wuhan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age>=18 years old, regardless of gender; 2. Diagnosis of sepsis according to Sepsis 3.0; 3. Diagnosed with AKI according to KIDGO classification and requiring CRRT treatment; 4. Patients or their guardians have a full understanding of the purpose and significance of this trial, volunteer to participate in this study and follow the study procedures, and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Estimated ICU hospitalization time 2 times the normal value), uncorrectable hypoxemia and tissue hypoperfusion, Lac>20mmoL/L, severe metabolic alkalosis, known citric acid allergy; (2) Namustat anticoagulation contraindications: patients with coagulation dysfunction or uncontrollable major bleeding, such as gastrointestinal hemorrhage, cerebral hemorrhage, etc., liver failure (TB> 2 times the normal value), known citric acid allergy; 3. Unable to establish appropriate vascular access; 4. Patients who need to undergo plasmapheresis and other blood purification treatments at the same time; 5. Patients whose hemodynamics are extremely unstable, judged by the investigator to be unsuitable for inclusion, or who require ECMO support; 6. Suffering from terminal malignant tumors, with an expected survival time of less than half a year; 7. Pregnant and lactating women; 8. CKD patients with regular dialysis needs; 9. Those who have used other investigational drugs or devices within 1 month before screening, or participated in other clinical trials at the same time; 10. Patients who are not suitable to participate in this study due to other reasons in the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of the first CRRT session; | — |
Secondary
| Measure | Time frame |
|---|---|
| Lactate clearance rate; | — |
Countries
China
Contacts
Public ContactJing Wang
Zhongnan Hospital of Wuhan University
Outcome results
None listed